T. Rowe Price Associates
ITCI

T. Rowe Price Associates’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

T. Rowe Price Associates’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-115,424
Closed -$15.2M – 3182
2025
Q1 		$15.2M Sell
115,424
-474,482
-80% -$59.1M ﹤0.01% 1018
2024
Q4 		$49.3M Sell
589,906
-452,549
-43% -$37.2M 0.01% 763
2024
Q3 		$76.3M Sell
1,042,455
-385,955
-27% -$29M 0.01% 630
2024
Q2 		$97.8M Buy
1,428,410
+224,442
+19% +$15.6M 0.01% 547
2024
Q1 		$83.3M Sell
1,203,968
-56,929
-5% -$3.91M 0.01% 590
2023
Q4 		$90.3M Buy
1,260,897
+604,328
+92% +$34.8M 0.01% 569
2023
Q3 		$34.2M Buy
656,569
+211
+0% +$12.3K 0.01% 786
2023
Q2 		$41.6M Buy
656,358
+112,424
+21% +$7.01M 0.01% 754
2023
Q1 		$29.5M Buy
543,934
+11,797
+2% +$570K ﹤0.01% 819
2022
Q4 		$28.2M Buy
532,137
+181,181
+52% +$9.08M ﹤0.01% 824
2022
Q3 		$16.3M Buy
350,956
+310,214
+761% +$16.2M ﹤0.01% 967
2022
Q2 		$2.33M Buy
40,742
+1,040
+3% +$59K ﹤0.01% 1557
2022
Q1 		$2.43M Buy
39,702
+3,513
+10% +$182K ﹤0.01% 1615
2021
Q4 		$1.89M Sell
36,189
-4,333
-11% -$182K ﹤0.01% 1742
2021
Q3 		$1.51M Buy
40,522
+4,279
+12% +$149K ﹤0.01% 1849
2021
Q2 		$1.48M Sell
36,243
-4,046
-10% -$150K ﹤0.01% 1872
2021
Q1 		$1.37M Buy
40,289
+8,799
+28% +$305K ﹤0.01% 1896
2020
Q4 		$1M Sell
31,490
-281,856
-90% -$7.41M ﹤0.01% 1942
2020
Q3 		$8.04M Sell
313,346
-648,403
-67% -$14.8M ﹤0.01% 1344
2020
Q2 		$24.7M Sell
961,749
-532,736
-36% -$10.8M ﹤0.01% 1090
2020
Q1 		$23M Buy
1,494,485
+201,249
+16% +$4.37M ﹤0.01% 1023
2019
Q4 		$44.4M Buy
1,293,236
+1,220,658
+1,682% +$14.6M 0.01% 958
2019
Q3 		$542K Sell
72,578
-282,922
-80% -$2.71M ﹤0.01% 2065
2019
Q2 		$4.61M Sell
355,500
-563
-0.2% -$7.22K ﹤0.01% 1406
2019
Q1 		$4.34M Buy
356,063
+5,100
+1% +$65.2K ﹤0.01% 1417
2018
Q4 		$4M Sell
350,963
-90,215
-20% -$1.46M ﹤0.01% 1429
2018
Q3 		$9.57M Sell
441,178
-400,010
-48% -$8.36M ﹤0.01% 1382
2018
Q2 		$14.9M Sell
841,188
-302,452
-26% -$6.14M ﹤0.01% 1278
2018
Q1 		$24.1M Buy
1,143,640
+1,119,204
+4,580% +$21.8M ﹤0.01% 1121
2017
Q4 		$354K Buy
24,436
+7,900
+48% +$122K ﹤0.01% 2221
2017
Q3 		$261K Buy
16,536
+2,400
+17% +$35.2K ﹤0.01% 2324
2017
Q2 		$176K Sell
14,136
-469,175
-97% -$5.44M ﹤0.01% 2405
2017
Q1 		$7.85M Sell
483,311
-33,311
-6% -$482K ﹤0.01% 1373
2016
Q4 		$7.8M Sell
516,622
-47,080
-8% -$665K ﹤0.01% 1356
2016
Q3 		$8.59M Buy
563,702
+554,095
+5,768% +$22.4M ﹤0.01% 1342
2016
Q2 		$373K Buy
9,607
+37
+0.4% +$1.33K ﹤0.01% 2084
2016
Q1 		$266K Buy
+9,570
New +$319K ﹤0.01% 2201

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

T. Rowe Price Associates's ITCI Position: Q2 2025 in Review

T. Rowe Price Associates sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 115,424 shares — an estimated $15.2M sold.

T. Rowe Price Associates first reported a position in ITCI in Q1 2016 and held it in 37 quarters. The position peaked at $97.8M in Q2 2024. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • T. Rowe Price Associates reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • T. Rowe Price Associates sold 115,424 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $15.2M.
  • T. Rowe Price Associates first reported a position in Intra-Cellular Therapies Inc. in Q1 2016 and held it in 37 quarters.
  • T. Rowe Price Associates's Intra-Cellular Therapies Inc. position peaked at $97.8M in Q2 2024.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on T. Rowe Price Associates's 13F filing for Q2 2025, filed 14 Aug 2025.